Two Drugs for Idiopathic Pulmonary Fibrosis Win Approval from U.S. FDA
Published By : 16 Oct 2014 | Published By : QYRESEARCH
Two new drugs, manufactured by Boehringer Ingelheim GmbH and Roche Holding AG (ROG), have won approval from the U.S. FDA. These drugs are the two medicines introduced in the U.S. market to fight idiopathic pulmonary fibrosis, a deadly lung disease.
The FDA stated that Boehringer’s Ofev, chemically known as nintedanib, and Roche’s Esbriet, chemically known as pirfenidone, has been approved for use in treatment of the deadly lung disease that kills 60 to 80 percent of its patients within duration of five years. The U.S. market did not, as of now, have a medicine against the condition.
Esbriet was acquired by Roche from InterMune Inc. in a recent deal that closed last month.
Jonathan Leff, from the research and development department at InterMune said that the company had spent nearly a decade in studying the disease and its dreadful nature. Amidst a multitude of failures, Esbriet now seems to be a solution that can turn a corner in the field.
Nearly 48,000 people are diagnosed with the disease every year in the U.S. Market potential of Esbriet led to its buyout from Basel, Roche at $8.3 billion at a time when InterMune was unprofitable.
Roche will reportedly charge nearly $94,000 per year for the therapy. Patients will be on the therapy for the rest of their lives due to the chronic nature of the disease. Boehringer did not comment about the price of Ofev.
Both the drugs were approved by the U.S. FDA in a fast-track manner. It is estimated that Esbriet may be able to generate nearly $1.6 billion worth sales in 2020 and nearly $2 billion by the end of 2030 for patients with idiopathic pulmonary fibrosis, analysts forecast.